Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

Publisher： Bentham Science Publishers

E-ISSN： 2212-4063|18|3|234-238

ISSN： 1871-529X

Source： Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol.18, Iss.3, 2018-12, pp. : 234-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib Mesylate in Chronic Myeloid Leukemia

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

By Carella Angelo Lerma Enrica

Annals of Hematology, Vol. 86, Iss. 10, 2007-10 ,pp. : 749-752

Springer Publishing Company

Access to resources Recommend Favorite

Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate

By Sonmez Mehmet Akagun Tulin Cobanoglu Umit Topbas Murat Erkut Nergiz Yilmaz Mustafa Ovali Ercument Omay Serdar Bedii

Hematology, Vol. 14, Iss. 4, 2009-08 ,pp. : 220-223

Maney Publishing

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite

Bilateral Toxoplasma Retinochoroiditis in a Patient with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

By Basu Soumyava Das Taraprasad Biswas Ghanshyam

Ocular Immunology and Inflammation, Vol. 18, Iss. 1, 2010-01 ,pp. : 64-65

Informa Healthcare

Access to resources Recommend Favorite